|Bid||337.00 x 1000|
|Ask||350.00 x 1100|
|Day's Range||334.71 - 338.83|
|52 Week Range||276.83 - 375.25|
|Beta (5Y Monthly)||0.35|
|PE Ratio (TTM)||50.55|
|Earnings Date||Apr 27, 2023|
|Forward Dividend & Yield||4.52 (1.32%)|
|Ex-Dividend Date||Feb 14, 2023|
|1y Target Est||388.56|
German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy costs and the effect of write-downs on development projects. Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year earlier. The Jardiance group of products, managed in a partnership with Eli Lilly, had 5.8 billion euros in sales, a currency-adjusted surge of 39.1%.
In the latest trading session, Eli Lilly (LLY) closed at $337.65, marking a +0.91% move from the previous day.
While growth stocks boomed in the era of easy money, value stocks have returned to form as the market's top performers in the current high interest rate environment. Now, value comes in many forms, such as a highly dependable dividend, an economically insensitive revenue stream, the quality of a company's management team, long-term growth drivers, and/or an attractive valuation. In the present risk-averse market, the most highly prized aspects of value stocks appear to be the dependability of a company's dividend, along with its ability to generate strong free cash flows regardless of the state of the broader economy.